Dernières nouvelles pour LogicMark (NASDAQ:LGMK) Stock

LogicMark

LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.

LogicMark Inc

<p>Researchers from Emory University, the University of Wisconsin-Madison and UC-Berkeley have identified a significant opportunity for <a href="https://www.benzinga.com/topic/psilocybin-assisted-therapy">psilocybin-assisted therapy</a> in the U.S. mental healthcare landscape. As U.S. News <a href="https://www.usnews.com/news/health-news/articles/2024-09-13/over-5-million-americans-could-benefit-if-psilocybin-approved-for-depression-study">reported</a>, if approved by the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a>, psilocybin could be used to treat depression, with an estimated<strong> 5.1 to 5.6 million</strong> Americans potentially benefiting from the therapy.</p>
<p>Examining a group of patients undergoing treatment for depression, researchers determined that psilocybin could be a game-changing solution, particularly for individuals suffering from major depressive disorder (MDD) or treatment-resistant depression (TRD). These conditions, which affect millions across the country, are typically unresponsive to standard treatments, underscoring the urgent need for new solutions.</p>
<h3 class="wp-block-heading"><strong>A Breakthrough Approach To Treating Depression</strong></h3>
<p>The study, <a href="https://pp.genomicpress.com/wp-content/uploads/2024/09/PP0025-Rab-2024.pdf">published</a> in Psychedelics<em> </em>by Genomic Press, explored the FDA's consideration of psilocybin from <a href="https://www.benzinga.com/markets/cannabis/22/11/29549541/the-strongest-magic-mushroom-species">Psilocybe cubensis</a> mushrooms as a <a href="https://www.benzinga.com/general/biotech/24/03/37665900/fda-grants-cybin-breakthrough-therapy-status-for-major-depression-psilocybin-therapy-company-anno">breakthrough therapy,</a> which is a designation that allows drugs with the potential to address life-threatening conditions like severe depression, to be fast-tracked through the approval process. If green-lighted, psilocybin would likely be reserved for individuals with the most severe forms of depression or those who have not responded to traditional treatments.</p>
<p>The study found that some 1.7 million Americans with TRD could immediately benefit from psilocybin-assisted therapy. When including those with MDD, the number of potential beneficiaries rises to 5.6 million. <strong>Dr. Syed Fayzan Rab</strong>, an MD candidate at Emory University and the study's lead author, highlighted the importance of recognizing the scope of this opportunity. "This underscores the importance of understanding the practical realities of rolling out this novel treatment on a large scale."</p>
<h3 class="wp-block-heading"><strong>A Market Ready To Take Off</strong></h3>
<p>Implications of this study go beyond healthcare. The psilocybin-assisted therapy market holds immense economic potential. A 2023 <a href="https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1293243/full">report</a> estimated that a single psilocybin-assisted therapy session could cost around $1,500 per patient. Considering the millions of individuals who may be eligible for treatment, this could translate into billions of dollars in revenue once psilocybin gains FDA approval.</p>
<p>Several companies are already preparing to capitalize on this potential market. <strong>Compass Pathways</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), <strong>Atai Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and <strong>Mindset Pharma</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MSSTF#OTC">MSSTF</a>) are among the pharmaceutical firms actively developing psilocybin-based treatments. </p>
<h3 class="wp-block-heading"><strong>Beyond Depression: Psilocybin's Expanding Horizon</strong></h3>
<p>While psilocybin's most immediate application lies in depression treatment, its therapeutic potential extends further. Ongoing studies are investigating psilocybin's efficacy in treating chronic pain and <a href="https://www.benzinga.com/topic/ptsd">post-traumatic stress disorder</a>. These developments signal that psilocybin could revolutionize not just mental healthcare but also the treatment of other chronic conditions.</p>
<p>However, psilocybin remains classified as a <a href="https://www.benzinga.com/topic/controlled-substances-act">Schedule I</a> drug at the federal level, meaning it is considered to have no accepted medical use and a high potential for abuse. This classification, shared with substances like marijuana, heroin and <a href="https://www.benzinga.com/topic/lsd">LSD</a>, complicates the path toward legalizing its medical use. </p>
<p>Despite these federal restrictions, several U.S. states and local jurisdictions have <a href="https://www.benzinga.com/topic/psychedelics-decriminalization">decriminalized psilocybin</a> in recent years, signaling a growing push for policy reform at higher levels. </p>
<p>"It's our hope that these findings spur productive discussions and proactive preparations to optimize the benefit to patients while minimizing unintended consequences," said <strong>Dr. Charles Raison</strong>, a professor of psychiatry at the University of Wisconsin and co-author of the study.  </p>
<p><em>Cover image made with A</em>I</p>


Cannabis

News

Psychedelics

Regulations

Health Care

ATAI

CMPS

MSSTF

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes

<p>Wells Fargo  analyst Joseph O'Dea   maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Overweight and raises the price target from $293 to $305.</p>


Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Rockwell Automation, Raises Price Target to $305

Guidance

PENN

Penn Entertainment Expects Q3 Retail Operations Adj EBITDAR In Range $465M-$475M

<ul>
<li><i>Companies jointly propose electric transmission projects to serve region's growing power demand through&nbsp;PJM's competitive planning process</i></li>
<li><i>Collaboration leverages expertise of industry leaders to propose comprehensive, cost-effective solutions that promote regional grid reliability</i></li>
</ul>
<p>RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Dominion Energy Virginia, American Electric Power and FirstEnergy Corp. have entered into an innovative joint planning agreement to propose several new regional electric transmission projects across multiple states within the PJM footprint.&nbsp;</p>
<p>The innovative collaboration comes at a time when efficient and cost-effective regional transmission development is essential and encouraged by the Federal Energy Regulatory Commission (FERC), the independent federal agency that regulates the interstate transmission of electricity.</p>
<p>Power demand in the PJM region is growing at an unprecedented pace due to rapid expansion of energy-intensive industries such as data centers, the electrification of transportation and heating, and increased manufacturing onshoring. At the same time, the region's power generation mix is changing as legacy generation is retired and more renewables are added to the grid.</p>


Dominion Energy, American Electric Power, FirstEnergy Reach Joint Planning Agreement To Propose Regional Transmission Projects Across PJM Footprint To Propose Comprehensive, Cost-Effective Solutions That Promote Regional Grid Reliability

WIIM

ELAN

Elanco shares are trading higher after the company received FDA approval for Credelio Quattro broad-spectrum canine oral parasiticide in a monthly dose.

<div>
<div><strong>Nutanix</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntnx#NASDAQ">NTNX</a>) shares have returned 26.2% year to date, outperforming the broader Zacks Computer and Technology sector&#39;s appreciation of 23.4%.</div>
<div>NTNX shares have also outperformed the Zacks Computer &ndash; IT Services industry and its peers like <strong>Unisys</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>), <strong>Evolv Technologies</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlv#NASDAQ">EVLV</a>) and <strong>Cerence</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crnc#NASDAQ">CRNC</a>).</div>
<div>Over the same time frame, Unisys has appreciated 0.2%, while Evolv Technologies and Cerence have declined 19.7% and 86.3%, respectively. The industry has appreciated 9.2% YTD.</div>
<div>NTNX&#39;s outperformance can be attributed to the steady adoption of hybrid cloud solutions, an increase in renewal and subscription business, and an expanding clientele.&nbsp;</div>
<div class="chart_embed">
<h2>Nutanix Price and Consensus</h2>
<p><img alt="Nutanix Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a2/1728310394.png" style="height:265px; width:581px" title="" /></p>
<p>Nutanix price-consensus-chart | Nutanix Quote</p>
</div>
<h2>Does Strong Clientele Justify NTNX&#39;s Premium Valuation?</h2>
<div>In fiscal 2024, approximately 76% of NTNX&#39;s end customers who have been its clients for 18 months or longer made a repeat purchase, reflecting a loyal customer base. Nutanix&#39;s total revenues for fiscal 2024 were $2.14 billion, of which 93.8% was from subscriptions.</div>
<div>NTNX stacks are usable with a vast library of operating systems like Microsoft and SAP, and existing customers have benefited from the hyper-converged infrastructure market.</div>
<div>However, NTNX shares are overvalued, as suggested by a Value Score of F.</div>
<div>In terms of the forward 12-month Price/Earnings ratio, NTNX is trading at 178.5X, higher than the Zacks Computer &amp; Technology sector&#39;s 26.83X.</div>
<div>So, the question for investors is - does an expanding clientele make Nutanix shares attractive despite a stretched valuation? Let&#39;s analyze.</div>
<h2>NTNX&#39;s Cloud Innovation Aids Prospects</h2>
<div>Nutanix is focusing on new releases and enhancements to the Nutanix Cloud Platform to aid long-term opportunities and to become a leader in modern application and data management platforms.</div>
<div>NTNX expanded its 14-year partnership with Dell Technologies to announce innovations like Dell XC Plus and Dell PowerFlex.</div>
<div>Nutanix Cloud Platform enables businesses to modernize IP footprints, integrate hybrid cloud models, and accelerate migration of workload to the public cloud to enhance cost-effectiveness and efficiency.</div>
<div>NTNX recently launched GPT-in-a-Box to aid in streamlining the adoption of GenAI by enterprises. It also launched Nutanix Data Services for Kubernetes, to provide consistent data services across virtual machines and container assets, and Nutanix Kubernetes Platform to allow simplification in the management of modern applications on-premise and in native public cloud service.</div>
<div>Nutanix announced a collaboration with NVIDIA to aid enterprises adopt GenAI easily.</div>
<div>Nutanix Cloud Clusters enable workloads to run seamlessly in private and public clouds while increasing automation and reducing the dependency on expensive proprietary solutions.</div>
<h2>Elongated Sales Cycle Concern for Nutanix</h2>
<div>In fiscal 2024, Nutanix&#39;s land and expand revenues suffered due to longer sales cycles, which have been elongated compared to historical levels.</div>
<div>NTNX&#39;s average contract term length in the fiscal fourth quarter was 3.1 years, 0.1 years higher than the fiscal third quarter.</div>
<div>Nutanix&#39;s customer base is increasing but is largely constituted of large deals leading to variability of timing and outcome.</div>
<div>As NTNX targets its sales efforts for large enterprises, it faces higher costs, greater competition, stiff price pressure, customization challenges, and lower predictability in its ability to complete the sale.</div>
<div>NTNX&#39;s operating expense for fiscal 2024 was $1.51 billion, up 7% over fiscal 2023. This increase can be attributed to an increase in research and development (increased 19% to $638 million) and sales and marketing expenses (increased 6% to $977 million). Higher operating expenses are likely to negatively impact bottom-line results in fiscal 2025.</div>
<h2>NTNX&#39;s Fiscal 2025 Outlook Positive</h2>
<div>For fiscal 2025, NTNX revenues are estimated in the range of $2.435-$2.465 billion, indicating year-over-year growth of 14% at the mid-point.</div>
<div>The Zacks Consensus Estimate for revenues is pegged at $2.45 billion, indicating year-over-year growth of 14.24%.</div>
<div>NTNX expects a non-GAAP operating margin in the band of 15.5-17%.</div>
<div>The consensus mark for fiscal 2025 earnings is pegged at $1.40 per share, up 2.9% in the past 30 days. The figure indicates a 6.87% year-over-year increase.</div>
<div>Nutanix expects free cash flow in the range of $540-$600 million, suggesting a free cash flow margin of 23% at the midpoint.</div>
<h2>NTNX Shares - To Buy, Hold or Sell?</h2>
<div>Macroeconomic challenges, including persistent inflation, are a concern for NTNX&#39;s prospects.</div>
<div>Stretched valuation, elongated sales cycle duration, and increasing operating expenses are concerns for investors.</div>
<div>Nutanix currently has a Zacks Rank #3 (Hold), which implies that investors should wait for a more favorable entry point into the stock.</div>
<div><a href="https://www.zacks.com/stock/news/2347040/nutanix-shares-up-26-ytd-how-should-investors-play-the-stock?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347040">To read this article on Zacks.com click here.</a></div>
</div>


Earnings

Large Cap

Macro Economic Events

Penny Stocks

Contracts

Small Cap

Economics

Markets

Tech

Trading Ideas

CRNC

EVLV

NTNX

Nutanix Shares Up 26% YTD: How Should Investors Play the Stock?

<p>Wells Fargo  analyst Joseph O'Dea   maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Overweight and raises the price target from $640 to $710.</p>


Wells Fargo Maintains Overweight on Parker Hannifin, Raises Price Target to $710

<ul>
<li>Credelio Quattro&#x2122; (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiii</li>
<li>Warming temperatures and changing consumer habits have increased parasite pressure and spread across geographies, bringing with them increased public health risk.</li>
<li>Experts recommend monthly treatment for zoonotic parasitesiv, like <i>Echinococcus granulosus</i>, a type of tapeworm.</li>
<li>Credelio Quattro launch expected in first quarter of 2025</li>
</ul>
<p>GREENFIELD, Ind., Oct. 7, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) today announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro&#x2122; (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), becoming the broadest approved canine oral parasiticide with its protection against six types of parasites—fleas, ticks, heartworms, and the three risky intestinal parasites—roundworms, hookwormsii and tapeworms. Credelio Quattro is a single, monthly chewable tablet for dogs eight weeks of age or older.</p>


Biotech

General

Elanco Receives FDA Approval For Credelio Quattro, The Broadest Canine Oral Parasiticide Protection In A Single Monthly Dose; Launch Expected In Q1 2025

<p>Wells Fargo  analyst Joseph O'Dea   maintains Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) with a Equal-Weight and raises the price target from $95 to $108.</p>


OTIS

Wells Fargo Maintains Equal-Weight on Otis Worldwide, Raises Price Target to $108

<p>Wells Fargo  analyst Joseph O'Dea   maintains Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) with a Equal-Weight and raises the price target from $570 to $615.</p>


Wells Fargo Maintains Equal-Weight on Lennox Intl, Raises Price Target to $615

<p><strong>Sonder Holdings Inc. (NASDAQ:</strong><a href="https://www.benzinga.com/stock/SOND#NASDAQ"><strong>SOND</strong></a><strong>, "Sonder" or the "Company"))) </strong>today announced that it has received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that since it remains delinquent in filing its Forms 10-Q for the periods ended March 31 and June 30, 2024 (the "Forms 10-Q"), respectively (the "Delinquent Filings"), the Staff has determined that the Company is non-compliant with Nasdaq Listing Rule 5250(c)(1). Previously, the Staff granted the Company an exception until September 30, 2024, to file all delinquent periodic reports. Additionally, the Company was previously deemed delayed on the filing of the&nbsp;Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"); however, the Company has since filed the 2023 Form 10-K on September 27, 2024, and the Staff determined that the Company complies with respect to the 2023 Form 10-K. As a result of the Delinquent Filings, the Company's common stock and warrants are subject to suspension in trading on October 10, 2024, and delisting from Nasdaq unless the Company appeals and requests a hearing before a Hearings Panel ("Hearings Panel") by 4:00 Eastern Time on October 8, 2024.</p>


SOND

Sonder Holdings Receives Nasdaq Staff Determination Letter; Has Requested Hearing Before Hearings Panel

<p>Insulation Supplies was established in 1986 and is headquartered in New Hope, Minnesota, near Minneapolis. Insulation Supplies generates over&nbsp;$22 million&nbsp;of annual revenue throughout Minnesota and the upper Midwest.</p>
<p>As a specialty distributor focused on residential and commercial end-markets, Insulation Supplies sells fiberglass insulation, spray foam insulation, cellulose insulation, and related insulation accessories and machinery.</p>


Installed Building Products Reveals Acquisition Of Wholesale Insulation Supply, Inc. Doing Business As Insulation Supplies; No Terms Disclosed; Deal Adds Over $22M Of Annual Revenue

<p>Wells Fargo  analyst Joe O'Dea   maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Overweight and raises the price target from $80 to $84.</p>


Wells Fargo Maintains Overweight on Johnson Controls Intl, Raises Price Target to $84

<p>Wells Fargo  analyst Joseph O'Dea   maintains Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) with a Overweight and raises the price target from $100 to $110.</p>


Wells Fargo Maintains Overweight on Ingersoll Rand, Raises Price Target to $110

<p><i><strong>CHS and Denim Health are working together to enhance patient experience and generate efficiencies across CHS' proprietary call center that serves approximately 1,000 primary care providers</strong></i></p>
<p>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) ("CHS") and Denim Health have announced a development partnership that is aimed at revolutionizing the call center experience for patients through the implementation of conversational AI in the CHS Patient Access Center ("PAC"). The PAC is a centralized call center serving nearly 1,000 CHS-affiliated primary care providers and handling more than 25,000 inbound calls daily.</p>
<p>CHS and Denim Health have been working together since late 2023 to develop call center workflows that incorporate conversational AI. Following a successful pilot, CHS has deployed Denim Health's AI bot across the PAC environment, making this advanced technology available for all inbound calls.</p>
<p>In the initial phase, conversational AI is being used to authenticate the identity of callers, understand the reason for their calls, and capture additional information to assist agents, before transferring callers to PAC agents. Denim Health's AI bot has successfully authenticated the identities of existing patients with zero instances of misidentification. In cases where the bot is unable to verify a caller's identity, the call is seamlessly transferred to a PAC agent for further assistance.</p>
<p>This use case already has resulted in a notable reduction in total call time, creating immediate efficiencies. The enterprise-wide deployment also lays the groundwork for additional use cases, which will include using conversational AI, machine learning, and natural language processing to enable patient self-scheduling, care gap closures, and other common transactions.</p>
<p>While consumers have become increasingly comfortable completing call center interactions using bots and automated systems, callers to the CHS Patient Access Center retain the option to speak with a human agent at any time during their call experience.</p>


Community Health Systems And Denim Health Announce A Development Partnership Designed To Broadly Scale Conversational AI Across The CHS Patient Access Center That Serves ~1,000 Primary Care Providers

<p>Wells Fargo  analyst Joseph O'Dea   maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Underweight and raises the price target from $236 to $250.</p>


Wells Fargo Maintains Underweight on Illinois Tool Works, Raises Price Target to $250

SXTC

China SXT Pharmaceuticals Received Noncompliance Notice

<p><strong>Amazon.com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares are trading lower Monday following a downgrade from Wells Fargo. The stock also appears to be facing selling pressure after a federal judge said the Federal Trade Commission (FTC) can proceed with its <a href="https://www.benzinga.com/markets/equities/24/09/41108210/amazon-secures-partial-victory-over-ftc-in-monopoly-case-trial-split-into-two-by-judge">lawsuit against the company</a>.</p>
<p><strong>What To Know:</strong> Wells Fargo analyst Ken Gawrelski downgraded Amazon from Overweight to Equal-Weight on Monday and lowered the price target from&nbsp;$225&nbsp;to&nbsp;$183, citing slowing growth and stiffer competition, per <a href="https://www.cnbc.com/2024/10/07/wells-fargo-downgrades-amazon-on-slowing-growth-expectations-walmart-competition.html">CNBC</a>.</p>
<p>The Wells Fargo analyst believes Amazon remains a margin expansion story. Although the market is already bracing for weaker operating income into the end of the year, Gawrelski cautioned that margin expansion could be capped through the first half of 2025. </p>
<p>A federal judge&#8217;s ruling related to the FTC&#8217;s antitrust lawsuit also appears to be adding to the selling pressure on Amazon shares Monday.</p>
<p>According to an AP News <a href="https://apnews.com/article/amazon-antitrust-lawsuit-ftc-case-bbd55b3403978183360fe0bc7e3f08cc">report</a>, the order that was issued by Judge <strong>John H. Chun</strong> last week was unsealed on Monday, showing the judge will allow the FTC to proceed with its lawsuit against Amazon. A trial is expected to be held in October 2026.</p>
<p>"We are pleased with the court's decision and look forward to moving this case forward," FTC spokesperson <strong>Doug Farrar</strong> reportedly said in a statement. </p>
<p>"The ways Amazon illegally maintains its monopolies and the harm they cause—including suppressed competition and higher prices for shoppers and sellers—will be on full display at trial."</p>
<p><strong>See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41211507/doj-to-file-remedies-framework-against-google-jp-morgan-sees-alphabet-eps-to-drop-1">DOJ To File Remedies Framework Against Google: JP Morgan Sees Alphabet EPS To Drop 10%, &#8216;Negative Headlines&#8217; Likely</a></strong></p>
<p>The FTC has alleged that Amazon is abusing its marketplace positioning to inflate prices, overcharge sellers and stifle competition on its platform. Several state attorney generals are also accusing the e-commerce giant of violating antitrust laws. The report indicates that Judge Chun allowed some state claims to proceed, but also dismissed some claims made by New Jersey, Pennsylvania, Oklahoma and Maryland this week.</p>
<p><strong>AMZN Price Action:</strong> <a href="http://benzinga.com/quote/amzn">Amazon shares</a> were down 3.06% at $180.80 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: Shutterstock.</em></p>


Downgrades

Legal

Movers

AMZN

Amazon Stock Is Sliding Monday: What's Going On?

<p>TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) has been awarded an integrated Engineering, Procurement, Construction, and Installation (iEPCI&#x2122;) contract(1) by bp for its greenfield Kaskida development in the Gulf of Mexico.</p>
<p>The contract covers the design and manufacture of subsea production systems, including 20,000 psi (20K) standardized subsea trees and manifolds. The scope also includes the design, manufacture, and installation of subsea umbilicals, risers, and flowlines.</p>
<p>The award follows an integrated Front End Engineering and Design (iFEED&#xAE;) study by TechnipFMC.</p>
<p>Jonathan Landes, President, Subsea for TechnipFMC, commented: "Our innovative high-pressure solutions are key to helping unlock the most economically attractive opportunities in the Paleogene. Kaskida is our latest iEPCI&#x2122; project with bp and is emblematic of our longstanding collaboration. Through early engagement, we're leveraging the breadth of our technological and integration capabilities to help bp successfully deliver Kaskida."</p>
<p><i>(1) For TechnipFMC, the contract is categorized as a "substantial" award, valued between $250 million and $500 million. This award was included in inbound orders in the third quarter of 2024.</i></p>


TechnipFMC Awarded Integrated Engineering, Procurement, Construction, And Installation Contract For bp's Greenfield 20K Development In The Paleogene; Contract Valued Between $250M-$500M

<p>Wells Fargo  analyst Joseph O'Dea   maintains Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) with a Equal-Weight and raises the price target from $400 to $445.</p>


HUBB

Wells Fargo Maintains Equal-Weight on Hubbell, Raises Price Target to $445

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>LogicMark</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lgmk-stock-quote/"><strong>LGMK</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>LogicMark reported earnings per share of -85 cents.</li><li>The company reported revenue of $2.61 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/lgmk-stock-earnings-logicmark-for-q1-of-2024/">LGMK Stock Earnings: LogicMark Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LGMK Stock Earnings: LogicMark Reported Results for Q1 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news this morning!</p>



<p>Moving stocks are new contracts and agreements, ongoing rallies, retreats from rallies and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Ampco-Pittsburgh</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ap-stock-quote/"><strong>AP</strong></a>) stock is rocketing more than 75% on <a href="https://www.nasdaq.com/press-release/ampco-pittsburgh-subsidiaries-announce-commercial-contract-wins-and-strong-growth">commercial contract wins and backlog news</a>.</li>



<li><strong>Vivopower</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/"><strong>VVPR</strong></a>) shares are soaring over 54% on a <a href="https://www.nasdaq.com/press-release/vivopower-secures-extension-us-34m-loan-financing-facility-agreement-2024-07-09">new extended loan facility agreement</a>.</li>



<li><strong>Seelos Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/"><strong>SEEL</strong></a>) stock is surging more than 33% alongside heavy pre-market trading.</li>



<li><strong>Naas Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/naas-stock-quote/"><strong>NAAS</strong></a>) shares are rising over 27% with strong early morning trading.</li>



<li><strong>Soligenix </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/"><strong>SNGX</strong></a>) stock is increasing more than 25% as it <a href="https://investorplace.com/2024/07/why-is-soligenix-sngx-stock-up-296-today/">continues to rally</a>.</li>



<li><strong>Cumulus Media</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmls-stock-quote/"><strong>CMLS</strong></a>) shares are gaining over 19% without any clear news this morning.</li>



<li><strong>Smart for Life</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/smfl-stock-quote/"><strong>SMFL</strong></a>) stock is climbing more than 18% after <a href="https://www.nasdaq.com/press-release/smart-life-announces-appointment-jessica-walters-chief-marketing-officer-2024-07-09">naming a new Chief Marketing Officer</a>.</li>



<li><strong>A2Z Smart Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/az-stock-quote/"><strong>AZ</strong></a>) shares are heading over 15% higher as they continue a recent rally.</li>



<li><strong>Aehr Test Systems</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aehr-stock-quote/"><strong>AEHR</strong></a>) stock is jumping more than 15% <a href="https://seekingalpha.com/news/4123175-aehr-test-systems-stock-up-14-after-raises-fy24-revenue-guidance-above-estimates">after increasing its guidance</a>.</li>



<li><strong>Neuronetics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/stim-stock-quote/"><strong>STIM</strong></a>) shares are up over 13% despite a lack of news on Wednesday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>LegalZoom.com</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lz-stock-quote/"><strong>LZ</strong></a>) stock is diving 26% after <a href="https://www.nasdaq.com/press-release/legalzoom-announces-leadership-transition-2024-07-09">announcing leadership changes</a>.</li>



<li><strong>MariaDB </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/mrdb-stock-quote/"><strong>MRDB</strong></a>) shares are tumbling more than 25% without any apparent news this morning.</li>



<li><strong>AFC Gamma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/afcg-stock-quote/"><strong>AFCG</strong></a>) stock is taking an over 20% beating on Wednesday morning.</li>



<li><strong>Zapp Electric Vehicles</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/"><strong>ZAPP</strong></a>) shares are retreating more than 17% <a href="https://www.marketwatch.com/amp/story/zapp-electric-shares-jump-68-after-june-china-auto-sales-report-160c0c60">following a rally yesterday</a>.</li>



<li><strong>LogicMark </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/lgmk-stock-quote/"><strong>LGMK</strong></a>) stock is falling over 16% after rallying on Tuesday.</li>



<li><strong>Sify Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sify-stock-quote/"><strong>SIFY</strong></a>) shares are dropping more than 16% today.</li>



<li><strong>Stardust Power</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/"><strong>SDST</strong></a>) stock is decreasing over 15% <a href="https://markets.businessinsider.com/news/stocks/stardust-power-jumps-45-in-pre-market-ahead-of-nasdaq-debut-1033539375">after rallying with its debut</a>.</li>



<li><strong>Top KingWin</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcjh-stock-quote/"><strong>TCJH</strong></a>) shares are slipping more than 14% this morning.</li>



<li><strong>Applied DNA Sciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/apdn-stock-quote/"><strong>APDN</strong></a>) stock is dipping over 14% today.</li>



<li><strong>Connexa Sports Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/"><strong>YYAI</strong></a>) shares close out our pre-market stock movers down more than 13% on Wednesday.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-10th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

LogicMark stock sinks after it prices its $4.5M public offering

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!</p>



<p>Moving stocks are new patents, insider buying, a company name change and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>PS International Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/psig-stock-quote/"><strong>PSIG</strong></a>) stock is rocketing more than 81% alongside heavy pre-market trading.</li>



<li><strong>Ainos </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/aimd-stock-quote/"><strong>AIMD</strong></a>) shares are soaring over 47% after <a href="https://www.nasdaq.com/press-release/ainos-secures-exclusive-multi-regions-invention-patent-licenses-strategic-partner">securing new patent licenses</a>.</li>



<li><strong>LogicMark </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/lgmk-stock-quote/"><strong>LGMK</strong></a>) stock is surging more than 38% alongside details of an upcoming <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318511278&amp;type=PDF&amp;symbol=LGMK&amp;cdn=5653ec5b97d2382396937934a20579e2&amp;companyName=LogicMark+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-08-09">special shareholder meeting</a>.</li>



<li><strong>VS Media</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/"><strong>VSME</strong></a>) shares are gaining over 25% despite a lack of news this morning.</li>



<li><strong>Genius </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/gns-stock-quote/"><strong>GNS</strong></a>) stock is increasing more than 19% <a href="https://www.nasdaq.com/press-release/genius-group-founder-ceo-roger-james-hamilton-purchase-10-million-shares-2024-08-09">on insider buying</a>.</li>



<li><strong>FSD Pharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/"><strong>HUGE</strong></a>) shares are rising over 19% on <a href="https://www.nasdaq.com/press-release/fsd-pharma-announces-share-consolidation-and-name-change-2024-08-09">share consolidation and name change plans</a>.</li>



<li><strong>ProMIS Neurosciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmn-stock-quote/"><strong>PMN</strong></a>) stock is climbing more than 17% this morning.</li>



<li><strong>ConnectM Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntm-stock-quote/"><strong>CNTM</strong></a>) shares are heading over 17% higher without any clear news today.</li>



<li><strong>BioVie </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/bivi-stock-quote/"><strong>BIVI</strong></a>) stock is jumping more than 15% on Monday morning.</li>



<li><strong>Portage Biotech</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/"><strong>PRTG</strong></a>) shares are up over 14% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>iLearningEngines </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/"><strong>AILE</strong></a>) stock is plummeting more than 27% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318511870&amp;type=PDF&amp;symbol=AILE&amp;cdn=8f0ca76b44522478ea48d6b3e52f5445&amp;companyName=iLearningEngines+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-08-09">pricing a public offering</a>.</li>



<li><strong>Meta Materials</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmat-stock-quote/"><strong>MMAT</strong></a>) shares are diving over 17% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318508874&amp;type=PDF&amp;symbol=MMAT&amp;cdn=747b3fffafae953c1fe1c54f998009fd&amp;companyName=Meta+Materials+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-09">filing for bankruptcy</a>.</li>



<li><strong>Sonoma Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/"><strong>SNOA</strong></a>) stock is tumbling more than 15% after <a href="https://finance.yahoo.com/news/sonoma-pharmaceuticals-first-quarter-2025-120225512.html">missing fiscal Q1 2025 earnings estimates</a>.</li>



<li><strong>Tenon Medical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnon-stock-quote/"><strong>TNON</strong></a>) shares are taking an over 15% beating despite any clear news this morning.</li>



<li><strong>Humacyte </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/huma-stock-quote/"><strong>HUMA</strong></a>) stock is sliding more than 13% <a href="https://www.stocktitan.net/news/HUMA/humacyte-announces-fda-communication-of-additional-time-required-to-5oxy7ry3qlgj.html">on an update</a> from the Food and Drug Administration (FDA).</li>



<li><strong>Aditxt </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/"><strong>ADTX</strong></a>) shares are falling over 12% on a <a href="https://www.nasdaq.com/press-release/aditxt-announces-12-million-registered-direct-offering-priced-market-under-nasdaq">registered direct offering</a>.</li>



<li><strong>CareMax</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/"><strong>CMAX</strong></a>) stock is dropping close to 12% on a <a href="https://finance.yahoo.com/news/caremax-inc-cmax-reports-q2-224503059.html">Q2 loss and revenue miss</a>.</li>



<li><strong>Big Tree Cloud</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/"><strong>DSY</strong></a>) shares are decreasing more than 10% <a href="https://www.nasdaq.com/press-release/big-tree-cloud-holdings-limited-receives-nasdaq-notification-regarding-minimum-market">with a delisting notice</a>.</li>



<li><strong>Azitra&nbsp;</strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/"><strong>AZTR</strong></a>) stock is slipping over 10% this morning.</li>



<li><strong>Bright Minds Biosciences </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/drug-stock-quote/"><strong>DRUG</strong></a>) shares close out our pre-market stock movers down more than 10% today.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-aug-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

LogicMark Q2 Earnings Preview

Here's the major earnings after the close today

LogicMark GAAP EPS of -$0.96 beats by $0.11, revenue of $2.34M misses by $0.03M

LogicMark, Inc. (LGMK) Q2 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>LogicMark</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lgmk-stock-quote/"><strong>LGMK</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>LogicMark reported earnings per share of -96 cents. This was above the analyst estimate for EPS of -$1.07.</li><li>The company reported revenue of $2.34 million.</li><li>This was 1.43% worse than the analyst estimate for revenue of $2.37 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/lgmk-stock-earnings-logicmark-for-q2-of-2024/">LGMK Stock Earnings: LogicMark Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LGMK Stock Earnings: LogicMark Beats EPS, Misses Revenue for Q2 2024

LogicMark (LGMK) has shared an update. The latest company update includes forward-looking statements that predict future events or performance, wit...

LogicMark Issues Forward-Looking Statements and Cautions Investors

ACHV

ADTX

AEHR

AFCG

AILE

AIMD

APDN

ARMN

ASXC

AZTR

BEEM

BIVI

CMAX

CMLS

CNTM

CTSO

CURI

DPRO

DRRX

DRUG

FLUT

GROY

HIVE

HUGE

HUMA

IMOS

KNTNF

LAAC

LGMK

MMAT

MRCY

MRDB

NAAS

NVVE

NWHUF

OUST

PRTG

PSIG

QFIN

QUIK

REED

RKDA

SDST

SEEL

SHWZ

SIFY

SMFL

SNGX

SNOA

STIM

TCJH

TNON

VSME

VTGN

VVPR

WPRT

YYAI

ZAPP

ZVRA

Screenshot 2024-09-23 at 5.43.20 PM

Emerging Markets

Independent Living And Safety: How LogicMark&#39;s Innovations Are Helping To Address The Needs Of An Aging America

Screenshot 2024-08-19 at 5.18.45 PM

Movers & Shakers

LogicMark (NASDAQ: LGMK) Makes Expansion Push With Mobile Personal Safety App Aster As It Pivots From Medical Alerts With CPaaS Model

Press Releases

Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

LogicMark, Inc. to Announce Second Quarter 2024 Financial Results on August 13, 2024

Financing

LogicMark, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market

LogicMark, Inc. Announces Closing of $4.5 Million Public Offering Priced At-The-Market

LogicMark, Inc. Announces Second Quarter 2024 Financial Results;  Expansion Strategy into Personal Safety Markets Continues

Bitech Technologies (OTCQB: BTTC) Revolutionizes Grid Stability with Advanced Smart Energy Storage Solutions SIFY LGMK FCUV CBDW

Independent Living And Safety: How LogicMark's Innovations Are Helping To Address The Needs Of An Aging America

LAZR, LGMK, RIME, REGRF: Leaders Report Latest Advances in AI Transformation, Rolex Watch Market, LiDAR, and HealthTech for Aging

Comments

LogicMark

Actualités

Dernières nouvelles pour LogicMark (NASDAQ:LGMK) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL